{"title":"抗血管生成剂 aflibercept 对手术诱发的大鼠子宫内膜异位症的影响。","authors":"Caglayan Ates, Berna Dilbaz, Seval Yılmaz Ergani, Fuad Atabay","doi":"10.24875/CIRU.23000072","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.</p><p><strong>Material and methods: </strong>Surgically induced endometriosis in Wistar albino female rats. Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le). Then, Af, aflibercept, and Le received leuprolide acetate. The control group was not treated. The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score. Blood extracted for sacrifice was analyzed. Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31). Significance level was accepted as p < 0.05.</p><p><strong>Results: </strong>Aflibercept significantly reduced endometrial implant volume (p = 0.002). The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002). Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate. Aflibercept improved adhesions (p = 0.006).</p><p><strong>Conclusion: </strong>Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.</p>","PeriodicalId":93936,"journal":{"name":"Cirugia y cirujanos","volume":"92 1","pages":"10-19"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model.\",\"authors\":\"Caglayan Ates, Berna Dilbaz, Seval Yılmaz Ergani, Fuad Atabay\",\"doi\":\"10.24875/CIRU.23000072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.</p><p><strong>Material and methods: </strong>Surgically induced endometriosis in Wistar albino female rats. Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le). Then, Af, aflibercept, and Le received leuprolide acetate. The control group was not treated. The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score. Blood extracted for sacrifice was analyzed. Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31). Significance level was accepted as p < 0.05.</p><p><strong>Results: </strong>Aflibercept significantly reduced endometrial implant volume (p = 0.002). The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002). Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate. Aflibercept improved adhesions (p = 0.006).</p><p><strong>Conclusion: </strong>Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.</p>\",\"PeriodicalId\":93936,\"journal\":{\"name\":\"Cirugia y cirujanos\",\"volume\":\"92 1\",\"pages\":\"10-19\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cirugia y cirujanos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24875/CIRU.23000072\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia y cirujanos","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/CIRU.23000072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The effect of antiangiogenic agent aflibercept on surgically induced endometriosis in a rat model.
Objective: The aim of the study is to show for the first time how aflibercept affects endometriosis lesions.
Material and methods: Surgically induced endometriosis in Wistar albino female rats. Rats with endometriosis were randomly divided into three groups: control (Co), aflibercept (Af), and leuprolide acetate (Le). Then, Af, aflibercept, and Le received leuprolide acetate. The control group was not treated. The weights and changes in intra-abdominal adhesions of the rats before and after treatment were recorded according to the Blauer adhesion score. Blood extracted for sacrifice was analyzed. Endometriotic lesions were evaluated for size, volume, histology, and immunohistochemistry (vascular endothelial growth factor [VEGF] and CD31). Significance level was accepted as p < 0.05.
Results: Aflibercept significantly reduced endometrial implant volume (p = 0.002). The explant epithelial histological score showed a significant difference between aflibercept and leuprolide acetate (p = 0.006) and between aflibercept and control groups (p = 0.002). Aflibercept decreased VEGF-H and CD31 expression (p = 0.001) more than leuprolide acetate. Aflibercept improved adhesions (p = 0.006).
Conclusion: Aflibercept is more successful than leuprolide acetate in the treatment of endometriosis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
